Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
The drug, Dupixent, showed a reduction of at least 30% in the annualized rate of moderate or severe COPD in a pair of Phase 3 studies. The drug was previously approved for the treatment of other conditions, including atopic dermatitis and asthma. Shares of Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administration (FDA) The drug, Dupixent, is the first biologic medicine approved in the U.S. for the treatment of COPD, a respiratory disease that restricts airflow and damages the lungs. The treatment showed a reduction of at least 30% in the annualized rate of moderate or severe COPD in a pair of Phase 3 studies, the companies reported. COPD Approval Adds to Drug's Applications Dupixent was previously approved for the treatment of other conditions, including atopic dermatitis and asthma. Shares of Regeneron ticked up 0.2% Friday, while San
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD [Yahoo! Finance]Yahoo! Finance
- Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPDGlobeNewswire
- Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)GlobeNewswire
- Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024GlobeNewswire
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
REGN
Earnings
- 8/1/24 - Beat
REGN
Sec Filings
- 9/5/24 - Form 4
- 9/5/24 - Form 4
- 9/5/24 - Form 4
- REGN's page on the SEC website